TITLE

Mergers & Acquisitions Update

PUB. DATE
January 2006
SOURCE
PharmaWatch: Biotechnology;Jan2006, Vol. 5 Issue 1, p18
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
This article presents an update on merging and acquisitions in the pharmaceutical industry. American Pharmaceutical Partners will merge with its parent company American BioScience in order to form a fully integrated, global biopharmaceutical company and will be named as Abraxis BioScience. GlaxoSmithKline PLC (GSK) has acquired the Canadian vaccine maker ID Biomedical Corp. for $1.4 billion. The transaction is part of GSK's strategic planning to expand its vaccine research and production network. Cell Gensys has been acquired by Genzyme Corp. for $3.2 million cash.
ACCESSION #
19457304

 

Related Articles

  • GSK catches flu shot.  // Chemical Market Reporter;9/12/2005, Vol. 268 Issue 8, p5 

    Reports that United States-based pharmaceutical firm Glaxosmithkline PLC continued its aggressive pursuit of a top slot in the flu vaccines arena with its bid for Vancouver, British Columbia-based ID Biomedical Corp. Worth of the bid; Benefit of the acquisition to Glaxosmithkline;...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Oct2005, Vol. 4 Issue 10, p3 

    Focuses on recent developments in the pharmaceutical industry. Acquisition of Canadian vaccine maker ID BioMedical Corp. by GlaxoSmithKline PLC; Rejection by Chiron of a takeover bid by Novartis AG; Submission of new drug applications with the U.S. Food and Drug Administration, by Pfizer Inc....

  • Industry News Headlines April 15, 2004 - May 14, 2004.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p20 

    Reports developments in the biotechnology industry as of April 2004. Acquisition of Shire Pharmaceuticals by ID Biomedical Corp.; Details on the lawsuit filed by Biota against GlaxoSmithKline PLC for failure to promote influenza drug; Sale of Zonegran, an ani-epiletic drug to Eisai Inc.

  • American Pharmaceutical Partners to Merge with American BioScience. Rios, Maribel // Pharmaceutical Technology;Jan2006, Vol. 30 Issue 1, p24 

    The article reports that injectable-drug maker American Pharmaceutical Partners Inc. has announced plans to merge with the American BioScience Inc. The merger will create Abraxis BioScience, which will hold worldwide ownership rights to "Abraxane," a marketed treatment for metastatic breast...

  • Branded News.  // Drug Store News;10/10/2005, Vol. 27 Issue 13, p33 

    Reports on developments concerning the U.S. drugstore chain sector as of October 2005. Approval gained by Sanofi-Aventis SA in September from the Food and Drug Administration for an extended-release version of its popular insomnia medication, Ambien CR; ID Biomedical Corp.'s acquisition by...

  • APP, ABI merge and go global.  // Chemical Market Reporter;12/5/2005, Vol. 268 Issue 19, p35 

    The article reports that a definitive agreement was signed by American Pharmaceutical Partners Inc. with American BioScience Inc. (ABI) to consolidate in an all-stock transaction to form a stronger, fully integrated, global biopharmaceutical company with a market value of roughly $7.5 billion....

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;4/22/2002, Vol. 261 Issue 16, p8 

    Presents updates on the U.S. pharmaceutical industry as of April 2002. Company to be acquired by Biovail Corp.; Net income posted by Genzyme General; Agreement signed by GlaxoSmithKline plc.

  • TOP STORIES.  // MondayMorning;9/20/2010, Vol. 18 Issue 34, p1 

    The article offers news briefs concerning businesses related to the pharmaceutical industry. Genzyme Corp., a takeover target of Sanofi-Aventis SA, has agreed to sell its diagnostic testing unit to Laboratory Corp. of America Holdings. Stock price of Pluristem Therapeutics Inc. has surged 42...

  • Mergers & Acquisitions Update.  // PharmaWatch: Biotechnology;Oct2006, Vol. 5 Issue 10, p19 

    The article presents several news briefs related to mergers in the pharmaceutical industry. Orthodontix Inc. and Israeli biotechnology company Protalix Ltd. have signed a definitive merger agreement. OccuLogix, a company focused on the treatment of age-related eye disease, has acquired Solx. A...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics